Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Change in Accured Expenses of -$4.0 million for Q1 2026, down 339.43% year-over-year from $1.7 million in Q1 2025, and down 201.01% quarter-over-quarter from $4.0 million in Q4 2025.
Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$4.0 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 339.43% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 111.54% YoY), while the FY2025 annual figure was $4.2 million, down 42.03% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $4.0 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $7.6 million in Q3 2024, with the low at -$6.3 million in Q2 2025.
- The 5-year median for Change in Accured Expenses is $1.9 million (2024), against an average of $1.5 million.
- Peak annual rise in Change in Accured Expenses reached 184.95% in 2024, while the deepest fall reached 458.83% in 2024.
- Neumora Therapeutics' Change in Accured Expenses stood at $7.0 million in 2022, then sank by 130.73% to -$2.2 million in 2023, then surged by 184.95% to $1.8 million in 2024, then jumped by 116.89% to $4.0 million in 2025, then plunged by 201.01% to -$4.0 million in 2026.
- Business Quant data shows NMRA's Change in Accured Expenses at -$4.0 million in Q1 2026, $4.0 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.02 Mn |
| Mar 31, 2026 | -4.02 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Dec 31, 2024 | 1.84 Mn |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | 7.58 Mn |
| Sep 30, 2024 | 7.58 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | -4.11 Mn |
| Mar 31, 2024 | -4.11 Mn |
| Dec 31, 2023 | -2.16 Mn |
| Dec 31, 2023 | -2.16 Mn |